Welcome to our dedicated page for Glaukos SEC filings (Ticker: GKOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Glaukos’s latest 10-K sprawls across hundreds of pages detailing iStent sales trends, FDA trial timelines, and delicate MIGS reimbursement risks—crucial data that can decide an ophthalmic investor’s next move. Hunting for that information in raw SEC PDFs wastes time, especially when “Glaukos insider trading Form 4 transactions” or a sudden 8-K about a clinical milestone can shift the outlook overnight.
Stock Titan’s AI tackles the complexity head-on. It delivers “Glaukos annual report 10-K simplified,” flags every “Glaukos quarterly earnings report 10-Q filing,” and explains “Glaukos 8-K material events explained” in plain English. Need Glaukos SEC filings explained simply? With real-time alerts you’ll see “Glaukos Form 4 insider transactions real-time” the moment executives buy or sell shares. Our system pairs each filing with concise financial ratios, R&D spend summaries, and segment revenue visualizations, so understanding Glaukos SEC documents with AI becomes effortless.
Use the platform to:
- Track MIGS unit growth across quarters
- Monitor executive stock transactions Form 4 before macro catalysts
- Compare R&D intensity against peer device makers
- Review proxy statement executive compensation alongside performance
Every document is searchable, exportable, and linked to expert notes—perfect for anyone asking “How do I read Glaukos earnings report filing analysis?” Stop scrolling past jargon; start seeing only the disclosures that matter.
Camping World Holdings (CWH) Q2 2025 10-Q key takeaways
- Revenue rose 9.4% YoY to $1.98 bn; six-month sales up 6.9% to $3.39 bn.
- Profitability improved: gross profit +8% to $592 m; operating income +37% to $130 m. Operating margin expanded 130 bp to 6.6%.
- Net income attributable to CWH advanced to $30.2 m (EPS $0.48) from $9.8 m (EPS $0.22). Six-month EPS turned positive at $0.29 vs. –$0.28.
- Segment drivers: New-vehicle revenue +8.0%, Used-vehicle +19.0%, F&I +12.4%. Good Sam Services grew 3.2%.
- Expense trends: SG&A up 4.2% to $437 m; combined interest expense fell 19% to $51.8 m, supporting bottom-line growth.
- Balance sheet: cash declined to $118 m (–43% YTD) as inventories expanded $239 m and floor-plan notes rose $118 m. Long-term debt steady at $1.48 bn; total leverage 4.7 × equity.
- Cash flow pressure: YTD operating cash outflow of $44.6 m (vs. +$84.3 m LY) driven by working-capital build; investing cash outflow $180 m for capex & acquisitions.
- Shareholder returns: quarterly dividend maintained at $0.125/sh (paid $15.7 m YTD); no share repurchases apart from tax-withholding on RSUs.
- Other items: immaterial tax-asset restatement increased deferred tax asset by $43.8 m and APIC by $33.4 m.
Overall, stronger sales and cost control lifted earnings, but negative operating cash flow and higher inventory/floor-plan debt warrant monitoring.
FAQ
What is the current stock price of Glaukos (GKOS)?
What is the market cap of Glaukos (GKOS)?
What is the core focus of Glaukos Corporation?
How does Glaukos differentiate itself in the ophthalmic market?
What type of technology is central to Glaukos' products?
In what clinical scenarios are Glaukos devices primarily used?
How does Glaukos maintain its operational credibility?
What strategies does Glaukos employ to innovate in the medical device industry?
Who are the primary beneficiaries of Glaukos' products?
How does Glaukos address the challenges of a competitive medical device landscape?
